Therefore, since PDE5 inhibitors are safely and successfully used in patients suffering from different pathologies [56,57], our results may endorse their use as repurposed concurrent treatments to conventional anti-cancer agents to provide more effective options for breast cancer women. This evidence concerns the gene PDE5A and cancer.